v3.25.1

Deferred income - Movement in the non-current and current deferred income (Details) - EUR (€) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023
Disclosure of Deferred Income [Line Items] |  |
Deferred income, beginning balance | € 1,327,463,000 | € 1,989,230,000
Of which current portion : | 256,270,000 | 365,631,000
Reclassification to liabilities directly associated with assets in disposal group classified as held for sale |  | (60,000)
Significant financing component | (227,000) | (645,000)
Revenue recognition of upfront | (252,134,000) | (591,654,000)
Revenue recognition of milestones | (4,089,000) | (68,027,000)
Other movements | 339,000 | (1,382,000)
Deferred income, ending balance | 1,071,352,000 | 1,327,463,000
Of which current portion : | 232,476,000 | 256,270,000
Other. |  |
Disclosure of Deferred Income [Line Items] |  |
Deferred income, beginning balance | 2,032,000 | 3,474,000
Of which current portion : | 1,146,000 | 2,139,000
Reclassification to liabilities directly associated with assets in disposal group classified as held for sale |  | (60,000)
Other movements | 339,000 | (1,382,000)
Deferred income, ending balance | 2,371,000 | 2,032,000
Of which current portion : | 2,371,000 | 1,146,000
Collaboration agreement for filgotinib | Gilead [member] |  |
Disclosure of Deferred Income [Line Items] |  |
Deferred income, beginning balance | 26,268,000 | 456,352,000
Of which current portion : | 25,054,000 | 133,470,000
Significant financing component | (227,000) | (645,000)
Revenue recognition of upfront | (21,952,000) | (361,412,000)
Revenue recognition of milestones | (4,089,000) | (68,027,000)
Deferred income, ending balance |  | 26,268,000
Of which current portion : |  | 25,054,000
Gilead collaboration agreement for drug discovery platform | Gilead [member] |  |
Disclosure of Deferred Income [Line Items] |  |
Deferred income, beginning balance | 1,299,163,000 | 1,529,405,000
Of which current portion : | 230,070,000 | 230,022,000
Revenue recognition of upfront | (230,182,000) | (230,242,000)
Deferred income, ending balance | 1,068,981,000 | 1,299,163,000
Of which current portion : | € 230,105,000 | € 230,070,000

X
- Definition The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, other than contract liabilities, reclassified to liabilities related to assets held for sale. + References No definition available. + Details
Name: | glpg_DeferredIncomeOtherThanContractLiabilitiesReclassificationsToLiabilitiesRelatedToAssetsHeldForSale
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of adjustments to deferred income due to significant financing component. + References No definition available. + Details
Name: | glpg_DeferredIncomeSignificantFinancingComponent
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | glpg_DisclosureOfDeferredIncomeLineItems
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred Income in other movements. + References No definition available. + Details
Name: | glpg_IncreaseDecreaseInOtherDeferredIncome
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue recognized on milestone payments. + References No definition available. + Details
Name: | glpg_MilestonePaymentsRevenueRecognized
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of revenue recognized on upfront or license fees. + References No definition available. + Details
Name: | glpg_UpfrontOrLicenseFeesRevenueRecognised
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, other than contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DeferredIncomeOtherThanContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | glpg_DeferredIncomeAxis=glpg_OtherDeferredIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_GileadCollaborationAgreementForDrugDiscoveryPlatformMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |